A microfluidic biosensor for the diagnosis of chronic wasting disease

Sura A Muhsin; Amjed Abdullah; Estela Kobashigawa; Muthana Al-Amidie; Sherri Russell; Michael Z Zhang; Shuping Zhang; Mahmoud Almasri

doi:10.1038/s41378-023-00569-1

A microfluidic biosensor for the diagnosis of chronic wasting disease

Microsyst Nanoeng. 2023 Aug 21:9:104. doi: 10.1038/s41378-023-00569-1. eCollection 2023.

Authors

Sura A Muhsin¹, Amjed Abdullah¹, Estela Kobashigawa², Muthana Al-Amidie¹, Sherri Russell³, Michael Z Zhang², Shuping Zhang², Mahmoud Almasri¹

Affiliations

¹ University of Missouri-Columbia, Electrical Engineering and Computer Science, Columbia, MO USA.
² University of Missouri-Columbia, College of Veterinary Medicine, Veterinary Medical Diagnostic Laboratory, Columbia, MO USA.
³ Missouri Department of Conservation, Columbia, MO USA.

Abstract

Cervids are affected by a neurologic disease that is always fatal to individuals and has population effects. This disease is called chronic wasting disease (CWD) and is caused by a misfolded prion protein. The disease is transmitted via contact with contaminated body fluids and tissue or exposure to the environment, such as drinking water or food. Current CWD diagnosis depends on ELISA screening of cervid lymph nodes and subsequent immunohistochemistry (IHC) confirmation of ELISA-positive results. The disease has proven to be difficult to control in part because of sensitivity and specificity issues with the current test regimen. We have investigated an accurate, rapid, and low-cost microfluidic microelectromechanical system (MEMS) biosensing device for the detection of CWD pathologic prions in retropharyngeal lymph nodes (RLNs), which is the current standard type of CWD diagnostic sample. The device consists of three novel regions for concentrating, trapping, and detecting the prion. The detection region includes an array of electrodes coated with a monoclonal antibody against pathologic prions. The experimental conditions were optimized using an engineered prion control antigen. Testing could be completed in less than 1 hour with high sensitivity and selectivity. The biosensor detected the engineered prion antigen at a 1:24 dilution, while ELISA detected the same antigen at a 1:8 dilution. The relative limit of detection (rLOD) of the biosensor was a 1:1000 dilution of a known strong positive RLN sample, whereas ELISA showed a rLOD of 1:100 dilution. Thus, the biosensor was 10 times more sensitive than ELISA, which is the currently approved CWD diagnostic test. The biosensor's specificity and selectivity were confirmed using known negative RPLN samples, a negative control antibody (monoclonal antibody against bovine coronavirus BCV), and two negative control antigens (bluetongue virus and Epizootic hemorrhagic disease virus). The biosensor's ability to detect pathogenic prions was verified by testing proteinase-digested positive RLN samples.

Keywords: Electrical and electronic engineering; Nanoparticles.